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ABSTRACT
Objective International guidelines recommend the use of 
dual antiplatelet therapy (DAPT) after transcatheter aortic 
valve implantation (TAVI). The recommended duration of 
DAPT varies between guidelines. In this two-part study, 
we (1) performed a structured survey of 45 TAVI centres 
from around the world to determine if there is consensus 
among clinicians regarding antiplatelet therapy after TAVI; 
and then (2) performed a systematic review of all suitable 
studies (randomised controlled trials (RCTs) and registries) 
to determine if aspirin monotherapy can be used instead 
of DAPT.
Methods A structured electronic survey regarding 
antiplatelet use after TAVI was completed by 45 TAVI 
centres across Europe, Australasia and the USA. A 
systematic review of TAVI RCTs and registries was then 
performed comparing DAPT duration and incidence of 
stroke, bleeding and death. A variance weighted least 
squared metaregression was then performed to determine 
the relationship of antiplatelet therapy and adverse events.
Results 82.2% of centres routinely used DAPT after 
TAVI. Median duration was 3 months. 13.3% based their 
practice on guidelines. 11 781 patients (26 studies) were 
eligible for the metaregression. There was no benefit of 
DAPT over aspirin monotherapy for stroke (P=0.49), death 
(P=0.72) or bleeding (P=0.91).
Discussion Aspirin monotherapy appears to be as safe 
and effective as DAPT after TAVI.
IntRODuCtIOn
Transcatheter aortic valve implantation 
(TAVI) has been demonstrated to be supe-
rior to medical therapy in patients in whom 
surgical aortic valve replacement (AVR) 
is deemed too high risk.1 The use of TAVI 
continues to increase2 and, due to its success 
in high-risk patients, its role in intermedi-
ate-risk patients is being assessed.3–5 One 
of the most feared complications of TAVI 
is stroke. The incidence of periprocedural 
stroke varies from 1% to 11%.6 To mitigate 
the risk of stroke, dual antiplatelet therapy 
(DAPT) is prescribed periprocedurally and 
for a period of time after the procedure.
The optimal duration of antiplatelet 
therapy  post-procedure has not been convinc-
ingly defined. European7 and American8 9 
guidance differs. Additionally, different valve 
manufacturers suggest different durations of 
DAPT post-procedure and the randomised 
studies that have established TAVI also use 
varying durations of DAPT.1 10 Finally, little 
prospective randomised data have been gath-
ered to definitively answer this question.
Unfortunately, while helping to mitigate 
against stoke, DAPT is also associated with 
an inevitable increased risk of bleeding 
Key questions
What is already known about this subject?
Periprocedural stroke is a well-recognised 
complication of transcatheter aortic valve implantation 
(TAVI). Post-TAVI antiplatelet therapy is routinely 
employed in an attempt to mitigate the risk of stroke, 
with a cost of increased bleeding complications. 
There is a paucity of data available to inform optimal 
antiplatelet strategy after TAVI and this is reflected in 
uncertainty within published guidelines.
What does this study add?
This study presents data demonstrating the 
heterogeneity of real-world practice with regard to 
antiplatelet prescribing in TAVI. By synthesising the 
available evidence, we demonstrate in a meta-analysis 
of 11 781 patients that dual antiplatelet therapy (DAPT) 
after TAVI confers no benefit beyond 1 month in terms 
of stroke rate, overall mortality or major bleeding. 
Aspirin monotherapy may therefore be a sufficient 
antiplatelet therapy in the post-TAVI period.
How might this impact on clinical practice?
This study provides the most robust evidence to 
date advocating a more conservative approach to 
antiplatelet therapy following TAVI. These data may 
be used to unify clinical practice and reduce exposure 
to the potentially harmful effects of DAPT in this 
vulnerable patient population.
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complications which can cause significant morbidity and 
mortality.11 12 The risk of bleeding complication appears 
to be most acutely related to patients’ age, gender, renal 
function and frailty.13 14 The majority of patients in the 
‘high-risk’ TAVI group also fall into the category of being 
at ‘high risk’ for bleeding complications from DAPT. 
Defining the minimal duration of DAPT, which reduces 
stroke risk while minimising the risk of bleeding compli-
cations, is therefore important to minimise adverse events 
in this population.
In this two-part study, we first performed a structured 
survey of 45 TAVI sites to determine their preferred anti-
platelet regimen and then performed a systematic review 
of the literature, meta-analysis and meta-regression to 
determine if there is an optimal duration of DAPT, and 
the role of aspirin monotherapy following TAVI.
MetHODs
tAVI survey
Up to 298 TAVI centres were identified worldwide using a 
TAVI implanters registry. An online structured question-
naire was issued to each centre to establish current prac-
tice with regard to DAPT. The duration of DAPT used, 
and the reasons why this was preferred, were ascertained. 
A copy of the original questionnaire is available in online 
supplementary appendix 1.
search strategy
We performed a systematic search of the MEDLINE, 
Cochrane and Embase databases (from 2006 to March 
2017) for all studies of TAVI. Our search strings included 
‘Transcatheter Aortic Valve Implantation’, ‘Transcatheter 
aortic valve replacement’, ‘antiplatelet’, ‘aspirin’, ‘clopi-
dogrel’ or ‘antithrombotic’. Bibliographies were hand-
searched for relevant studies, reviews and meta-analyses to 
identify further eligible studies. Abstracts were reviewed 
for suitability and articles were accordingly retrieved. The 
search and meta-analysis were performed in accordance 
with published guidance.
Inclusion and exclusion criteria
We considered all studies of TAVI. Studies were eligible 
if they reported mortality, stroke, bleeding and the 
antithrombotic regimen after TAVI. Both observa-
tional studies and randomised controlled trials (RCTs) 
were identified. We excluded studies of the transapical 
approach due to the inherent increased risk with this 
approach.15 16 We excluded animal studies, case reports, 
conference abstracts, meta-analyses and reviews from the 
final selection.
Analysis
The primary endpoints were stroke, all-cause mortality 
and major bleeding, and outcome data regarding these 
were extracted from the included studies. The duration 
of DAPT was also extracted for each included study. We 
carried out a meta-analysis of TAVI studies, in accordance 
with published guidance.17 These data were synthesised 
and meta-analysed using inverse-variance weighting and 
the Restricted Effects Maximum Likelihood (REML) 
method to provide a pooled estimate. A mixed-effects 
metaregression was then performed to determine the 
relationship of antiplatelet therapy and duration to 
adverse events by including DAPT duration as a contin-
uous moderator and study arm as a random effect. Heter-
ogeneity was assessed using the I2 statistic.2 18 Mean values 
are expressed as mean±SD unless otherwise stated. An 
unpaired t-test was used to compare between group data. 
The statistical programming environment R19 with the 




Forty-five TAVI sites across 12 countries participated. 
There was a breadth of experience in respondents: 33.3% 
had performed >200 cumulative procedures, 31.1% 
had performed 100–200 procedures and 35.6% had 
performed <100 procedures.
42.2% reported that their antiplatelet therapy policy 
was based on operator preference, 44.5% on local insti-
tutional policy and 13.3% on national and international 
guidelines (figure 1A). Only 11.1% reported adjusting 
antiplatelet therapy according to valve system used.
Pre-TAVI loading regimens were variable (figure 1B): 
40% were loaded with aspirin monotherapy, 6.6% were 
loaded with clopidogrel monotherapy and 24.4% were 
loaded with aspirin and clopidogrel. Twenty-nine per 
cent of centres did not load with any antiplatelet therapy. 
Antiplatelet therapy after TAVI was similarly variable 
(figure 1C): 82.2% reported using DAPT with 17.8% 
using monotherapy. Overall, 46.7% used 3 months, 
22.2% used 6 months, 4.4% used 1 month and 2.2% used 
12 months of DAPT therapy.
In patients on long-term oral anticoagulation (OAC) 
44.4% used antiplatelet monotherapy, 20% used 
DAPT and 35.6% did not use additional antiplatelet 
therapy. Duration of concomitant antiplatelet mono-
therapy in patients on OAC after TAVI was variable: 
Aspirin for 1 month was 15%, 3 months 10%, 6 months 
10% and long term 20%; clopidogrel for 1 month was 
10%, 3 months 20% and 6 months 15%.
systematic search
A total of 11 781 patients (26 studies) were suitably iden-
tified for inclusion3 10 20–44 (figure 2).
Characteristics of included studies
Characteristics of included studies are shown in online 
supplementary appendix 2.
Meta -analysis
The meta-analysis of mortality showed an overall all-cause 
mortality rate of 11% (95% CI 8% to 15%, P<0.001; 
I2=91.5%, P<0.001 for heterogeneity). The meta-analysis 
of stroke showed an overall stroke rate of 4% (95% CI 3% 
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to 6%, P<0.001; I2=65.8%, P<0.001 for heterogeneity). 
The meta-analysis of bleeding showed an overall rate of 
major bleeding of 11% (95% CI 6% to 17%, P<0.001; 
I2=96%, P<0.001 for heterogeneity).
All outcomes are at time to last follow-up across all 
studies.
Metaregression
Mixed-effects meta-regression was performed using DAPT 
duration as a continuous moderator and study as a random 
effect. Metaregression showed no significant interaction 
between DAPT duration and mortality (figure 3, β=0.02; 
95% CI −0.09 to 0.14; P=0.72; I2=96.7%; P for heteroge-
neity <0.001), stroke (figure 4, β=0.04; 95% CI −0.08 to 
0.17; P=0.49; I2=64%; P for heterogeneity <0.001) and 
bleeding (figure 5, β=−0.02; 95% CI −0.27 to 0.24; P=0.91; 
I2=97%; P for heterogeneity <0.001).
DIsCussIOn
In this study, we have found that: (1) there is large vari-
ance in the antiplatelet regimens used by different TAVI 
operators, with the majority of operators relying on 
personal or institutional policies rather than guideline 
recommendations; (2) compared with DAPT, aspirin 
monotherapy demonstrated similar protection against 
stroke; and (3) if DAPT is preferred, 1 month appears to 
be sufficient.
The meta-analysis presented is, by some margin, the 
largest addressing the question of the optimal anti-
platelet strategy following TAVI. In this field, where 
adequately sized, high-quality RCTs are currently lacking, 
this represents the most comprehensive analysis to date 
to inform clinical practice.
In addition to providing the largest and most contem-
porary data available, our study has further unique 
aspects. First, we have performed a structured survey that 
highlights the patterns of antithrombotic use by TAVI 
operators in clinical practice, and the rationale behind 
this. Furthermore, we have gone on to perform a metare-
gression using antiplatelet strategy as a moderator. This 
additional analysis confirms that prolonged DAPT had 
no effect on clinical outcomes, and helps give clinicians 
further confidence in limiting the duration of DAPT or 
using a single antiplatelet strategy for their patients.
Disparity between guidelines and clinical practice
Current guideline recommendations on antithrombotic 
therapy after TAVI are not uniform, and the strength of 
recommendations is not strong. The 2014 and 20178 9 
American Heart Association/American College of Cardi-
ology (ACC) guidelines on valvular heart disease suggest 
aspirin lifelong plus clopidogrel for 6 months ‘may be 
reasonable’, corresponding to a strength of recommen-
dation class of IIb. The level of evidence is classified as 
level C, indicating the lowest possible level of certainty 
(very limited populations evaluated, only consensus 
opinion of experts, case studies or standards of care). 
The 2017 ACC Expert Consensus Document45 on the 
care of patients after TAVI states that the current standard 
antithrombotic therapy after TAVI should be clopidogrel 
75 mg orally daily for 3–6 months with oral aspirin 
75–100 mg daily lifelong. The European Society of Cardi-
olog y guidelines on valvular heart disease7 do not make a 
specific recommendation for the duration of DAPT after 
TAVI, but simply state that a combination of low-dose 
aspirin and a thienopyridine should be used early after 
TAVI, followed by aspirin or a thienopyridine alone. The 
Figure 1 Results of structured survey of 45 TAVI centres. Panel (A) shows the basis behind decisions made for antithrombotic 
treatment after TAVI; panel (B) shows antiplatelet loading regimens before TAVI; panel (C) shows longer term antiplatelet 
strategy after TAVI. DAPT, dual antiplatelet therapy; TAVI, transcatheter aortic valve implantation. 
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definition of ‘early’ is not provided, leaving this open to 
interpretation by clinicians. Position statements from 
the Canadian Cardiovascular Society (CCS)46 (DAPT 
for 1–3 months) and American College of Cardiology 
Foundation (ACCF)/American Association for Thoracic 
Surgery (AATS)/Society for Cardiovascular Angiography 
and Interventions (SCAI)/Society of Thoracic Surgeons 
(STS)47 (DAPT for 3–6 months) give similar recommen-
dations.
Clinicians treating patients after TAVI are therefore 
provided with guideline recommendations that are not 
uniform across guideline bodies, are not specific with 
regard to the duration of DAPT recommended within 
individual guidelines and are made with the lowest levels 
of recommendation and weakest strength. This is a reflec-
tion of the paucity of evidence available in the field, and 
has likely contributed to the heterogeneous patterns of 
antithrombotic therapy clinicians are using.
For the first time, in this study, we present contempo-
rary, real-world clinical practice data with regard to anti-
platelet prescribing following TAVI, and the rationale 
behind treatment choices made by clinicians. This has 
provided an insight into how treating clinicians chose to 
interpret the available data, along with guideline recom-
mendations and their own clinical judgement to inform 
the choice of antithrombotic therapy for patients under-
going TAVI.
The majority of the clinicians surveyed do not base 
their decisions on antithrombotic regimens after TAVI on 
guideline recommendation (only 13.3%); rather, the vast 
majority base their decisions on personal preference or 
local institutional policy. This may be a reflection of the 
variance in recommendations between different guideline 
bodies, as well as the weak strength of recommendation 
and low class of evidence. The guideline recommenda-
tions are in turn a reflection of the absence of strong 
Figure 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart showing the search 
strategy for the systematic review, meta-analysis and metaregression.
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Figure 3 Metaregression showing the relationship between mortality and antiplatelet strategy. The x-axis shows DAPT 
duration, including aspirin monotherapy on the far left (blue panel). The y-axis shows the incidence of mortality. Individual 
studies are represented by circles, with study size weighting giving varying sizes. The red line denotes the gradient (β), with 
there being of no benefit in terms of DAPT over aspirin for mortality. DAPT, dual antiplatelet therapy. 
Figure 4 Metaregression showing the relationship between stroke and antiplatelet strategy. The x-axis shows DAPT duration, 
including aspirin monotherapy on the far left (blue panel). The y-axis shows the incidence of stroke. Individual studies are 
represented by circles, with study size weighting giving varying sizes. The red line denotes the gradient (β), with there being 
of no benefit in terms of DAPT over aspirin for stroke. DAPT, dual antiplatelet therapy. 
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randomised data in the field. The most commonly used 
duration of DAPT in our structured survey was 3 months 
(57% of respondents), while only 5% of centres used a 
shorter term policy (1 month).
Only 11.1% of operators choose their antithrombotic 
regimen according to the valve type inserted. The recom-
mendation for the Edwards SAPIEN series of valves is 
6 months of DAPT followed by aspirin lifelong; this is 
because this was the regimen used in the Placement of 
Aortic Transcatheter Valves (PARTNER) series of trials.3 
After the implantation of a CoreValve, the recommenda-
tion is for 3 months of DAPT then aspirin lifelong as this 
was the suggested strategy in the CoreValve trials.10
Optimal duration of DAPt
The majority of centres used DAPT after TAVI. The most 
common duration was 3 months with only 5% of centres 
using 1-month DAPT. This study demonstrates that there 
was no additional benefit of durations of DAPT longer than 
1 month with regard to the prevention of stroke or death.
There was no difference in bleeding rate between DAPT 
durations in this analysis. This may be a reflection of the 
heterogeneous definitions of bleeding between the studies.
Other studies have demonstrated the clear bleeding 
risk of prolonged DAPT.34 Although these studies did 
not include patients undergoing TAVI, their findings 
are likely to be applicable to the TAVI population given 
the comparatively high prevalence of renal impairment, 
underlying anaemia, frailty and other comorbidities that 
increase the propensity to bleed. It is therefore reasonable 
to conclude that should DAPT be preferred, the duration 
should be limited to 1 month.
Aspirin monotherapy is equivalent to DAPt
Guidelines recommend DAPT after TAVI, but as 
described above these are empirical recommendations 
based largely on expert consensus view. In the absence 
of RCT data, the recommendation for DAPT over aspirin 
monotherapy has been founded on extrapolation of 
data advocating DAPT following implantation of drug-
eluting coronary stents. However, there are fundamental 
differences in the thrombotic tendencies of TAVI valves 
and coronary stents, which limit the acceptability of this 
assumption. Important differences include the increased 
size and the bioprosthetic nature of TAVI valves. Further-
more, the advanced age, frailty and comorbidity of 
the current cohort of patients undergoing TAVI make 
bleeding complications more likely.
This analysis suggests DAPT may not be necessary. 
Aspirin monotherapy was found to be equivalent to all 
durations of DAPT in terms of stroke prevention and 
death. This is consistent with two small randomised 
trials26 42 (total of 199 patients) which have compared 
DAPT with aspirin monotherapy, as well as two non-ran-
domised studies28 33 (total of 463 patients). When consid-
ered alongside our analysis of 11 781 patients, there 
appears to be a consistent signal that aspirin mono-
therapy is as effective as DAPT at preventing stroke.
The recently published randomised controlled ARTE 
trial (Aspirin Versus Aspirin+Clopidogrel Following TAVI) 
Figure 5 Metaregression showing the relationship between bleeding and antiplatelet strategy. The x-axis shows DAPT 
duration, including aspirin monotherapy on the far left (blue panel). The y-axis shows the incidence of stroke. Individual studies 
are represented by circles, with study size weighting giving varying sizes. The red line denotes the gradient (β), with there being 
of no statistical difference between aspirin and DAPT for bleeding. DAPT, dual antiplatelet therapy. 
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was prematurely halted following an excess of major and 
life-threatening bleeds in the DAPT allocated group. 
Importantly, no increased risk of stroke was observed in 
those patients randomised to aspirin monotherapy. The 
findings therefore from this small trial comprising just 222 
patients would concur with the conclusions of this much 
larger meta-analysis, specifically that DAPT does not confer 
additional advantage over aspirin monotherapy.48
Potential role of new oral anticoagulants
Recent data have shown that subclinical valve leaflet 
thrombosis is more common after TAVI than surgical 
aortic valve replacement with bioprosthetic valves,49 and 
that this may lead to an increased risk of stroke. There-
fore, there is interest in the potential role of oral antico-
agulants, particularly non-vitamin K oral anticoagulants 
(NOAC) for antithrombotic therapy after TAVI. The role 
of NOACs after TAVI is being evaluated in prospective 
RCTs ( ClinicalTrials. gov Identifier: NCT02664649) and 
these data may inform future guideline recommenda-
tions regarding antithrombotic therapy after TAVI.
limitations
To limit the possibility of a false positive result, we have 
used a random effects analysis. However, it remains 
unclear how the number of studies, the relative weights 
of each study, the extent of heterogeneity between 
studies and the potential for aggregation bias all influ-
ence the probability of any metaregression producing 
false positive or false negative results. We assessed publi-
cation bias using a Funnel plot, but accept that this does 
not completely exclude the possibility of publication bias. 
Therefore, as with any other meta-analysis, any conclu-
sions from this study should be interpreted with this 
uncertainty in mind. The number of patients treated with 
aspirin monotherapy was much lower than those treated 
with DAPT, probably as a reflection of the current guide-
line recommendations. One could argue that this may 
limit the comparability of these cohorts. However, the 
event rates seen in the monotherapy groups are similar 
to the DAPT groups, and furthermore short durations 
of DAPT were as safe and effective as longer durations 
of DAPT; this provides support to the idea that aspirin 
monotherapy may be sufficient.
There was no uniform definition of bleeding. This may 
have masked any effect longer DAPT durations may have 
had on bleeding. A further explanation for the lack of 
effect of DAPT on bleeding may lie in the fact that some 
TAVI trials have excluded patients with recent bleeding 
events or at particularly high risk for bleeding. This incurs 
an inevitable selection bias which may have affected our 
results. The lack of effect of DAPT on bleeding should 
therefore be interpreted with caution.
COnClusIOn
Aspirin monotherapy appears to be as safe and effective 
as DAPT.
Contributors All authors fulfil the International Committee of Medical Journal 
Editors (ICMJE) recommendations for authorship. Conceived and designed the 
research: YA, SS. Performed statistical analysis: YA, MSS, JPH, AA. Acquired the 
data: YA, OD, MSS, CC, AA, AF, NS, BA, GK, GM, IM. Drafted the manuscript: YA, 
OD, CR, CC, RP, RJ, DF, JM, SS. Made critical revision of the manuscript for key 
intellectual content: YA, OD, CR, JPH, MSS, CC, DF, JM, GM, IM, SS.
Funding This work was supported by the National Institute of Health Research 
Biomedical Research Centre at Imperial College London.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The corresponding author agrees to share the source 
data upon reasonable request.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve 
replacement for inoperable severe aortic stenosis. N Engl J Med 
2012;366:1696–704.
 2. Mohr FW, Holzhey D, Möllmann H, et al. The German aortic valve 
registry: 1-year results from 13,680 patients with aortic valve 
disease. Eur J Cardiothorac Surg 2014;46:808–16.
 3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical 
aortic-valve replacement in intermediate-risk patients. N Engl J Med 
Overseas Ed 2016;374:1609–20.
 4. Zhou Y, Wang Y, Wu Y, et al. Transcatheter versus surgical aortic 
valve replacement in low to intermediate risk patients: A meta-
analysis of randomized and observational studies. Int J Cardiol 
2017;228:723–8.
 5. Søndergaard L, Steinbrüchel DA, Ihlemann N, et al. Two-year 
outcomes in patients with severe aortic valve stenosis randomized 
to transcatheter versus surgical aortic valve replacement. Circulation 
2016;9:e003665.
 6. Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early 
cerebrovascular events in patients with aortic stenosis undergoing 
transcatheter aortic valve replacement. J Am Coll Cardiol 
2016;68:673–84.
 7. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the 
management of valvular heart disease (version 2012): the joint task 
force on the management of valvular heart disease of the European 
Society of Cardiology (ESC) and the European Association for 
Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012;33:2451–96.
 8. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline 
for the Management of Patients With Valvular Heart Disease: 
Executive Summary. J Am Coll Cardiol 2014;63:2438–88.
 9. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused 
Update of the 2014 AHA/ACC Guideline for the Management 
of Patients With Valvular Heart Disease. J Am Coll Cardiol 
2017;70:252–89.
 10. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-
valve replacement with a self-expanding prosthesis. N Engl J Med 
2014;370:1790–8.
 11. Ducrocq G, Schulte PJ, Becker RC, et al. Association of 
spontaneous and procedure-related bleeds with short- and long-
term mortality after acute coronary syndromes: an analysis from the 
PLATO trial. EuroIntervention 2015;11:737–45.
 12. Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- Versus Long-Term 
Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. J 
Am Coll Cardiol 2015;65:1092–102.
 13. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict 
bleeding in patients with acute coronary syndromes. J Am Coll 
Cardiol 2010;55:2556–66.
 14. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced Age, 
Antithrombotic Strategy, and Bleeding in Non–ST-Segment Elevation 
Acute Coronary Syndromes. J Am Coll Cardiol 2009;53:1021–30.
 15. Onorati F, D'Onofrio A, Biancari F, et al. Aortic Valve Replacement 
in Redo-Scenarios: A Comparison Between Traditional Aortic Valve 
group.bmj.com on February 6, 2018 - Published by http://openheart.bmj.com/Downloaded from 
Open Heart
8 Ahmad Y, et al. Open Heart 2017;5:e000748. doi:10.1136/openhrt-2017-000748
Replacement (TAVR) and Transapical-TAVR from Two Real-World 
Multicenter Registries. J Heart Valve Dis 2015;24:669–78.
 16. Koifman E, Magalhaes M, Kiramijyan S, et al. Impact of transfemoral 
versus transapical access on mortality among patients with severe 
aortic stenosis undergoing transcatheter aortic valve replacement. 
Cardiovasc Revasc Med 2016;17:318–21.
 17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) 2015 
statement. Syst Rev 2015;4:1.
 18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-
analysis. Stat Med 2002;21:1539–58.
 19. R Development Core Team. R: A language and environment for 
statistical computing. Vienna, Austria: R Foundation for Statistical 
Computing, 2013. http://www. R- project. org/
 20. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day 
outcomes following transcatheter aortic valve implantation using the 
third generation (18 Fr) corevalve revalving system: results from the 
multicentre, expanded evaluation registry 1-year following CE mark 
approval. EuroIntervention 2008;4:242–9.
 21. Petronio AS, De Carlo M, Bedogni F, et al. Safety and efficacy of 
the subclavian approach for transcatheter aortic valve implantation 
with the CoreValve revalving system. Circ Cardiovasc Interv 
2010;3:359–66.
 22. Avinée G, Durand E, Elhatimi S, et al. Trends over the past 4 years 
in population characteristics, 30-day outcomes and 1-year survival 
in patients treated with transcatheter aortic valve implantation. Arch 
Cardiovasc Dis 2016;109:457–64.
 23. Vahanian A, Urena M, Walther T, et al. Thirty-day outcomes in 
patients at intermediate risk for surgery from the SAPIEN 3 European 
approval trial. EuroIntervention 2016;12:e235–e243.
 24. Meredith IT, Walters DL, Dumonteil N, et al. 1-year outcomes with 
the fully repositionable and retrievable lotus transcatheter aortic 
replacement valve in 120 high-risk surgical patients with severe 
aortic stenosis: results of the REPRISE II study. JACC Cardiovasc 
Interv 2016;9:376–84.
 25. Huczek Z, Kochman J, Grygier M, et al. Pre-procedural dual 
antiplatelet therapy and bleeding events following transcatheter 
aortic valve implantation (TAVI). Thromb Res 2015;136:112–7.
 26. Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet 
therapy for TAVI) study: a pilot randomized study comparing 
double to single antiplatelet therapy for transcatheter aortic valve 
implantation. Int J Cardiol 2014;174:624–7.
 27. Meredith IT, Worthley SG, Whitbourn RJ, et al. Transfemoral aortic 
valve replacement with the repositionable Lotus Valve System in 
high surgical risk patients: the REPRISE I study. EuroIntervention 
2014;9:1264–70.
 28. Durand E, Blanchard D, Chassaing S, et al. Comparison of two 
antiplatelet therapy strategies in patients undergoing transcatheter 
aortic valve implantation. Am J Cardiol 2014;113:355–60.
 29. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve 
replacement using a self-expanding bioprosthesis in patients with 
severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 
2014;63:1972–81.
 30. Meredith Am IT, Walters DL, Dumonteil N, et al. Transcatheter 
aortic valve replacement for severe symptomatic aortic 
stenosis using a repositionable valve system: 30-day primary 
endpoint results from the REPRISE II study. J Am Coll Cardiol 
2014;64:1339–48.
 31. Abramowitz Y, Banai S, Katz G, et al. Comparison of early and 
late outcomes of TAVI alone compared to TAVI plus PCI in aortic 
stenosis patients with and without coronary artery disease. Catheter 
Cardiovasc Interv 2014;83:649–54.
 32. Czerwińska-Jelonkiewicz K, Witkowski A, Dąbrowski M, et al. 
Antithrombotic therapy - predictor of early and long-term bleeding 
complications after transcatheter aortic valve implantation. Arch Med 
Sci 2013;9:1062–70.
 33. Poliacikova P, Cockburn J, de Belder A, et al. Antiplatelet and 
antithrombotic treatment after transcatheter aortic valve implantation 
- comparison of regimes. J Invasive Cardiol 2013;25:544–8.
 34. Tchetche D, Van der Boon RM, Dumonteil N, et al. Adverse impact of 
bleeding and transfusion on the outcome post-transcatheter aortic 
valve implantation: insights from the Pooled-RotterdAm-Milano-
Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative. Am 
Heart J 2012;164:402–9.
 35. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter 
aortic-valve implantation in high-risk patients. N Engl J Med 
2012;366:1705–15.
 36. Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve 
implantation: first results from a multi-centre real-world registry. Eur 
Heart J 2011;32:198–204.
 37. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical 
aortic-valve replacement in high-risk patients. N Engl J Med 
2011;364:2187–98.
 38. Nuis RJ, Van Mieghem NM, Schultz CJ, et al. Frequency and causes 
of stroke during or after transcatheter aortic valve implantation. Am J 
Cardiol 2012;109:1637–43.
 39. Lefèvre T, Kappetein AP, Wolner E, et al. One year follow-up of the 
multi-centre European PARTNER transcatheter heart valve study. Eur 
Heart J 2011;32:148–57.
 40. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and 
predictors of early and late mortality after transcatheter aortic valve 
implantation in 663 patients with severe aortic stenosis. Circulation 
2011;123:299–308.
 41. Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic valve 
implantation: early results of the FRANCE (FRench Aortic National 
CoreValve and Edwards) registry. Eur Heart J 2011;32:191–7.
 42. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy 
versus aspirin alone in patients undergoing transcatheter aortic valve 
implantation. Am J Cardiol 2011;108:1772–6.
 43. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic 
valve implantation for the treatment of severe symptomatic aortic 
stenosis in patients at very high or prohibitive surgical risk: acute and 
late outcomes of the multicenter Canadian experience. J Am Coll 
Cardiol 2010;55:1080–90.
 44. Avanzas P, Muñoz-García AJ, Segura J, et al. Percutaneous 
implantation of the CoreValve self-expanding aortic valve prosthesis 
in patients with severe aortic stenosis: early experience in Spain. Rev 
Esp Cardiol 2010;63:141–8.
 45. Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC expert 
consensus decision pathway for transcatheter aortic valve 
replacement in the management of adults with aortic stenosis: a 
report of the American college of cardiology task force on clinical 
expert consensus documents. J Am Coll Cardiol 2017;69:1313–46.
 46. Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve 
implantation: A canadian cardiovascular society position statement. 
Can J Cardiol 2012;28:520–8.
 47. Holmes DR, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/
STS expert consensus document on transcatheter aortic valve 
replacement. J Am Coll Cardiol 2012;59:1200–54.
 48. Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin 
plus clopidogrel as antithrombotic treatment following transcatheter 
aortic valve replacement with a balloon-expandable valve: the ARTE 
(aspirin versus aspirin + clopidogrel following transcatheter aortic 
valve implantation) randomized clinical trial. JACC Cardiovasc Interv 
2017;10:1357–65.
 49. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet 
thrombosis in surgical and transcatheter bioprosthetic aortic valves: 
an observational study. Lancet 2017;389:2383–92.
group.bmj.com on February 6, 2018 - Published by http://openheart.bmj.com/Downloaded from 
meta-analysis
transcatheter aortic valve implantation: a 
Optimal antiplatelet strategy after
and Sayan Sen
MalikKanaganayagam, Darrel Francis, Jamil Mayet, Ghada Mikhail, Iqbal 
Jabbour, Ahran Arnold, Angela Frame, Nilesh Sutaria, Ben Ariff, Gajen
Matthew Shun-Shin, Christopher Cook, Ricardo Petraco, Richard 
Yousif Ahmad, Ozan Demir, Christopher Rajkumar, James P Howard,
doi: 10.1136/openhrt-2017-000748
2018 5: Open Heart
 http://openheart.bmj.com/content/5/1/e000748




This article cites 48 articles, 15 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on February 6, 2018 - Published by http://openheart.bmj.com/Downloaded from 
